Skip to search formSkip to main contentSkip to account menu

RU 28965

Known as: RU-28965, RU28965 
National Institutes of Health

Related topics

Related topics

3 relations
RU 965Rulide

Broader (1)

Roxithromycin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1989
1989
副鼻腔炎に対するRoxithromycin (RU28965) の薬効評価
1989
1989
[Treatment of severe respiratory infection. Legionella pneumonia].
  • A. Saito
  • Nihon Kyobu Shikkan Gakkai zasshi
  • 1989
  • Corpus ID: 25324028
This paper discusses the evaluation of new macrolides and new quinolones for the treatment of Legionnaires' disease in in vitro… 
1987
1987
In vitro susceptibility of Mycobacterium avium to a new macrolide (RU-28965).
The in vitro susceptibility of Mycobacterium avium to RU-28965 alone and in combination with rifampin, isoniazid, and… 
1987
1987
Roxithromycin (RU28965) in the treatment of respiratory tract infections
1986
1986
InVitro Activity oftheNewMacrolide Antibiotic Roxithromycin (RU28965) against Clinical Isolates ofHaemophilus influenzae
1985
1985
[RU 28965, a new semi-synthetic macrolide. Bioavailability and pharmacokinetic profile after oral administration].
The plasma concentration of RU 28965, a new semisynthetic macrolide, was monitored for 24 h after single 400 mg oral doses in 8… 
1985
1985
[In vitro, activity of a new macrolide (RU 28965) against Chlamydia trachomatis and Ureaplasma urealyticum].
1983
1983
InVitro Evaluation ofThreeNewMacrolide Antimicrobial Agents, RU28965, RU29065, andRU29702, andComparisons withOtherOrally Administered Drugs
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)